GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Ceftaroline (Teflaro)

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug4 sources available - open source summaries, references and comparisons

Teflaro / Ceftaroline fosamil

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (4)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Teflaro - product and source limitations

The pediatric table uses a different renal metric. Confirm the patient's age, indication and infusion instructions.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Teflaro - product and source limitations

Historical source

Original GlobalRPh source

Choose a product and source Teflaro | Product label Teflaro | GlobalRPh RX passage All evidence
Product / population
Preserved GlobalRPh source, not a freshly verified product label
Renal measure
Use the method specified in the original source
Source revision
Historical source; revision not established here
Retrieved
2026-09-05 (not the revision date)

Historical source: not automatically current. Review current official labeling and separately attributed additions before use.

Indications and usage

Teflaro (ceftaroline fosamil) is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible S. aureus (including methicillin-susceptible and methicillin-resistant isolates), S. pyogenes, S. agalactiae, E. coli, K. pneumoniae and K. oxytoca.

Community-acquired bacterial pneumonia (CABP): S. pneumoniae (including concurrent bacteremia), S. aureus (methicillin-susceptible isolates only), H. influenzae, K. pneumoniae, K. oxytoca and E. coli.

Use only for proven or strongly suspected susceptible bacterial ABSSSI or CABP. Obtain appropriate specimens to isolate and identify causative organisms and determine susceptibility. When available, culture and susceptibility information should guide selection or modification; otherwise local epidemiology and susceptibility patterns may contribute.

Usual Dosing (Adults)

Adults >=18 years: 600 mg IV every 12 hours, infused over 1 hour. Duration is guided by severity/site and clinical and bacteriological progress: ABSSSI 5 to 14 days; CABP 5 to 7 days.

Renal Dosing

Cockcroft-Gault creatinine clearance:

CrCl (mL/min)Dose
>50No adjustment
>30 to <=50400 mg IV over 1 hour every 12 hours
>=15 to <=30300 mg IV over 1 hour every 12 hours
ESRD <15, including hemodialysis200 mg IV over 1 hour every 12 hours

Hemodialysis

Teflaro is hemodialyzable. Administer after hemodialysis on dialysis days.

Source revision: Historical source; revision not established here | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://globalrph.com/renal/ceftaroline/

Scope: Preserved historical source; no fresh clinical approval GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Teflaro - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 43, posted Nov 17, 2025

Renal measure: Cockcroft-Gault CrCl, mL/min

Read this dated source finding
Rxlist

Teflaro - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

Teflaro - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Ceftaroline fosamil (Teflaro), adult IV infusion

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Teflaro - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Teflaro - product and source limitations

The pediatric table uses a different renal metric. Confirm the patient's age, indication and infusion instructions.

How to use this: Apply only to the stated formulation, indication and renal population.

Teflaro - labeled renal guidanceTeflaro - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeTeflaro - labeled renal guidanceTeflaro - selected RX renal passageUCSF - ceftaroline: standard and severe-infection schedules
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/ceftaroline/

Indications and usage

Teflaro (ceftaroline fosamil) is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible S. aureus (including methicillin-susceptible and methicillin-resistant isolates), S. pyogenes, S. agalactiae, E. coli, K. pneumoniae and K. oxytoca.

Community-acquired bacterial pneumonia (CABP): S. pneumoniae (including concurrent bacteremia), S. aureus (methicillin-susceptible isolates only), H. influenzae, K. pneumoniae, K. oxytoca and E. coli.

Use only for proven or strongly suspected susceptible bacterial ABSSSI or CABP. Obtain appropriate specimens to isolate and identify causative organisms and determine susceptibility. When available, culture and susceptibility information should guide selection or modification; otherwise local epidemiology and susceptibility patterns may contribute.

GRPH-ceftaroline-01 · Source section: Indications and usageRenal section finder

Usual Dosing (Adults)

Adults >=18 years: 600 mg IV every 12 hours, infused over 1 hour. Duration is guided by severity/site and clinical and bacteriological progress: ABSSSI 5 to 14 days; CABP 5 to 7 days.

GRPH-ceftaroline-02 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Cockcroft-Gault creatinine clearance:

CrCl (mL/min)Dose
>50No adjustment
>30 to <=50400 mg IV over 1 hour every 12 hours
>=15 to <=30300 mg IV over 1 hour every 12 hours
ESRD <15, including hemodialysis200 mg IV over 1 hour every 12 hours
GRPH-ceftaroline-03 · Source section: Renal DosingRenal section finder

Hemodialysis

Teflaro is hemodialyzable. Administer after hemodialysis on dialysis days.

GRPH-ceftaroline-04 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Teflaro - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Ceftaroline fosamil (Teflaro), adult IV infusion

Renal method: Cockcroft-Gault CrCl, mL/min
Source date: DailyMed SPL version 43, posted Nov 17, 2025
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2, adult renal impairment dosing table

Limits that apply to these rows

The pediatric table uses a different renal metric. Confirm the patient's age, indication and infusion instructions.

Adult indication-specific ceftaroline renal regimens
Cockcroft-Gault CrCl (mL/min)Adult IV dose
>30 to 50400 mg every 12 hours
15 to 30300 mg every 12 hours
<15, including ESRD200 mg every 12 hours; after HD on dialysis days
Read the retained text before reformatting

Adult IV ceftaroline doses every 12 hours are 400 mg at CrCl above 30 through 50, 300 mg at 15 through 30, and 200 mg below 15 mL/min, including ESRD on HD. Administer after HD on dialysis days. The pediatric table uses a different renal metric. Confirm the patient's age, indication and infusion instructions.

RDM74-teflaro-official-1 · Source locator: Renal guidance: 2, adult renal impairment dosing table

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ecde48b-75a2-4beb-9999-369f3f61bb8a
Retrieved
2026-11-07
Renal-function method
Cockcroft-Gault CrCl, mL/min
Source date/version
DailyMed SPL version 43, posted Nov 17, 2025
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
3e2a602db6d6a0181fded404e6cc0d318e5f5284745a5f89da42d77aee0287cf
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Teflaro - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Ceftaroline fosamil (Teflaro), adult IV infusion

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror identifies the adult moderate, severe, and ESRD dose-reduction bands and includes hemodialysis.

RDM74-teflaro-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/teflaro-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
3c2c4d3335af17ce864b5ce468211a155808556866692e847fb997267e96e5fe
Separate professional-source layer

University and professional protocols

Professional

UCSF - ceftaroline: standard and severe-infection schedules

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

Printed bands overlap at 30. Higher-frequency dosing is institutional. Some serious infections with CrCl <50 or IHD may instead use every-12-hour dosing after ID pharmacy review.

Skin infection or CAP with low MRSA risk - IV
CrCl, mL/minSource-specific dose / instruction
>50600 mg every 12 hours
30-50400 mg every 12 hours
15-30300 mg every 12 hours
<15200 mg every 12 hours
Severe infection / suspected or documented MRSA pneumonia - IV
CrCl, mL/minSource-specific dose / instruction
>50600 mg every 8 hours
30-50400 mg every 8 hours
15-30300 mg every 8 hours
<15200 mg every 8 hours
Dialysis guidance - separate source-specific schedules
Ceftaroline - dialysis
Dialysis setting / indicationSource-specific schedule
IHD - first indication group200 mg every 12 hours
IHD - severe infection200 mg every 8 hours
Continuous HD - first indication group400 mg every 12 hours
Continuous HD - severe infection600 mg every 12 hours
Read the retained text before reformatting

CrCl bands >50 / 30-50 / 15-30 / <15 mL/min correspond to IV doses 600 / 400 / 300 / 200 mg. For skin infection or community-acquired pneumonia with low MRSA risk, give every 12 hours. For severe infection or pneumonia with suspected/documented MRSA, this institutional regimen uses every 8 hours. The source overlaps at 30.

Intermittent HD: 200 mg every 12 hours for the first group or every 8 hours for severe infection. Continuous HD: 400 mg every 12 hours for the first group or 600 mg every 12 hours for severe infection. Some serious infections with CrCl <50 or IHD may use every-12-hour dosing after ID pharmacy review. The higher-frequency strategy is source-specific.

RDM30-041-ceftaroline-1 · Source locator: UCSF - ceftaroline: standard and severe-infection schedules; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/ceftaroline
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
94f03f3b747f167199b2721687b95102008fc4b89f5cec0da6885c0d6f497b1b

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/ceftaroline/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
7e3b6ca10768863016fb9e9ebb538bee2daab5bb8a7ccc96a133991b901aaadd
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top